Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Variability of Platelet Reactivity on Antiplatelet Therapy in Neurointervention Procedure

  • Yi, Ho Jun (Department of Neurosurgery, Hangang Sacred Heart Hospital, Hallym University College of Medicine) ;
  • Hwang, Gyojun (Department of Neurosurgery, Hangang Sacred Heart Hospital, Hallym University College of Medicine) ;
  • Lee, Byoung Hun (Department of Neurosurgery, Hangang Sacred Heart Hospital, Hallym University College of Medicine)
  • Received : 2018.07.10
  • Accepted : 2018.08.01
  • Published : 2019.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

As more intracranial aneurysms and other cerebrovascular pathologies are treated with neurointervention procedure, thromboembolic events that frequently lead to serious neurological deficit or fatal outcomes are increasing. In order to prevent the thromboembolic events, antiplatelet therapy is used in most procedures including coil embolization, stenting, and flow diversion. However, because of variable individual pharmacodynamics responses to antiplatelet drugs, especially clopidogrel, it is difficult for clinicians to select the adequate antiplatelet regimen and its optimal dose. This article reviews the neurointervention literature related to antiplatelet therapy and suggests a strategy for tailoring antiplatelet therapy in individual patients undergoing neurointervention based on the results of platelet function testing.

Keywords

References

  1. Akbari SH, Reynolds MR, Kadkhodayan Y, Cross DT 3rd, Moran CJ : Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg 5 : 337-343, 2013 https://doi.org/10.1136/neurintsurg-2012-010334
  2. Aradi D, Collet JP, Mair J, Plebani M, Merkely B, Jaffe AS, et al. : Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost 113 : 221-230, 2015 https://doi.org/10.1160/TH14-05-0449
  3. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, et al. : Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36 : 1762-1771, 2015 https://doi.org/10.1093/eurheartj/ehv104
  4. Asai T, Miyachi S, Izumi T, Matsubara N, Haraguchi K, Yamanouchi T, et al. : Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms. J Neurointerv Surg 8 : 752-755, 2016 https://doi.org/10.1136/neurintsurg-2015-011727
  5. Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, et al. : Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 99 : 1518-1522, 2007 https://doi.org/10.1016/j.amjcard.2007.01.023
  6. Cattaneo M : Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 28 : 1673-1675, 2007 https://doi.org/10.1093/eurheartj/ehm232
  7. Chalouhi N, Tjoumakaris S, Dumont AS, Gonzalez LF, Randazzo C, Starke RM, et al. : Treatment of posterior circulation aneurysms with the pipeline embolization device. Neurosurgery 72 : 883-889, 2013 https://doi.org/10.1227/NEU.0b013e31828ba984
  8. Choi HH, Lee JJ, Cho YD, Han MH, Cho WS, Kim JE, et al. : Antiplatelet premedication for stent-assisted coil embolization of intracranial aneurysms: low-dose prasugrel vs clopidogrel. Neurosurgery 83 : 981-988, 2018 https://doi.org/10.1093/neuros/nyx591
  9. Daou B, Starke RM, Chalouhi N, Barros G, Tjoumakaris S, Rosenwasser RH, et al. : P2Y12 reaction units: effect on hemorrhagic and thromboembolic complications in patients with cerebral aneurysms treated with the pipeline embolization device. Neurosurgery 78 : 27-33, 2016 https://doi.org/10.1227/NEU.0000000000000978
  10. Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kadkhodayan Y, et al. : Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the pipeline embolization device. J Neurointerv Surg 5 Suppl 3 : iii3-iii10, 2013 https://doi.org/10.1136/neurintsurg-2012-010582
  11. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, et al. : The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 (6 Suppl) : 299S-339S, 2008 https://doi.org/10.1378/chest.08-0675
  12. Drazin D, Choulakian A, Nuno M, Kornbluth P, Alexander MJ : Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. J Neurointerv Surg 3 : 177-181, 2011 https://doi.org/10.1136/jnis.2010.004085
  13. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al. : Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81 : 735-741, 2007 https://doi.org/10.1038/sj.clpt.6100139
  14. Fifi JT, Brockington C, Narang J, Leesch W, Ewing SL, Bennet H, et al. : Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 34 : 716-720, 2013 https://doi.org/10.3174/ajnr.A3405
  15. Gaglia MA, Torguson R, Pakala R, Xue Z, Sardi G, Suddath WO, et al. : Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 24 : 529-534, 2011 https://doi.org/10.1111/j.1540-8183.2011.00670.x
  16. Godino C, Mendolicchio L, Figini F, Latib A, Sharp AS, Cosgrave J, et al. : Comparison of VerifyNow-P2Y12 test and flow cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? Thromb J 7 : 4, 2009 https://doi.org/10.1186/1477-9560-7-4
  17. Goh C, Churilov L, Mitchell P, Dowling R, Yan B : Clopidogrel hyperresponse and bleeding risk in neurointerventional procedures. AJNR Am J Neuroradiol 34 : 721-726, 2013 https://doi.org/10.3174/ajnr.A3418
  18. Gross L, Aradi D, Sibbing D : Platelet function testing in patients on antiplatelet medications. Semin Thromb Hemost 42 : 306-320, 2016 https://doi.org/10.1055/s-0035-1570083
  19. Ha EJ, Cho WS, Kim JE, Cho YD, Choi HH, Kim T, et al. : Prophylactic antiplatelet medication in endovascular treatment of intracranial aneurysms: low-dose prasugrel versus clopidogrel. AJNR Am J Neuroradiol 37 : 2060-2065, 2016 https://doi.org/10.3174/ajnr.A4864
  20. Hanel RA, Taussky P, Dixon T, Miller DA, Sapin M, Nordeen JD, et al. : Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. J Neurointerv Surg 6 : 320-322, 2014 https://doi.org/10.1136/neurintsurg-2013-010699
  21. Hwang G, Huh W, Lee JS, Villavicencio JB, Villamor RB Jr, Ahn SY, et al. : Standard vs modified antiplatelet preparation for preventing thromboembolic events in patients with high on-treatment platelet reactivity undergoing coil embolization for an unruptured intracranial aneurysm: a randomized clinical trial. JAMA Neurol 72 : 764-772, 2015 https://doi.org/10.1001/jamaneurol.2015.0654
  22. Kang HS, Kwon BJ, Kim JE, Han MH : Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol 31 : 1206-1210, 2010 https://doi.org/10.3174/ajnr.A2051
  23. Kashiwazaki D, Kuwayama N, Akioka N, Hayakawa Y, Kuroda S : The roles and issues of P2Y12 percent inhibition assessed by VerifyNow assay for patients undergoing Neurointervention: a prospective study. J Stroke Cerebrovasc Dis 23 : 1830-1836, 2014 https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.04.014
  24. Kim B, Kim K, Jeon P, Kim S, Kim H, Byun H, et al. : Thromboembolic complications in patients with clopidogrel resistance after coil embolization for unruptured intracranial aneurysms. AJNR Am J Neuroradiol 35 : 1786-1792, 2014 https://doi.org/10.3174/ajnr.A3955
  25. Kim CH, Hwang G, Kwon OK, Ban SP, Chinh ND, Tjahjadi M, et al. : P2Y12 reaction units threshold for implementing modified antiplatelet preparation in coil embolization of unruptured aneurysms: a prospective validation study. Radiology 282 : 542-551, 2017 https://doi.org/10.1148/radiol.2016160542
  26. Kim MH, Zhang HZ, Jung DK : Pharmacodynamic comparisons for single loading doses of prasugrel (30 mg) and clopidogrel (600 mg) in healthy Korean volunteers. Circ J 77 : 1253-1259, 2013 https://doi.org/10.1253/circj.CJ-12-0783
  27. Koerner H, Derveaux C, Alexandrou M, Graeber S, Roth C, Papanagiotou P, et al. : Do clopidogrel nonresponders have an increased risk of adverse events during supra-aortal angioplasty and stenting? Stroke Res Treat 2012 : 904534, 2012 https://doi.org/10.1155/2012/904534
  28. Kovacs EG, Katona E, Bereczky Z, Homorodi N, Balogh L, Toth E, et al. : Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb Res 133 : 811-816, 2014 https://doi.org/10.1016/j.thromres.2013.10.008
  29. Kovacs EG, Katona E, Bereczky Z, Homorodi N, Balogh L, Toth E, et al. : New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. Thromb Res 131 : 320-324, 2013 https://doi.org/10.1016/j.thromres.2013.01.033
  30. Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME : Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 29 : 1389-1394, 2008 https://doi.org/10.3174/ajnr.A1070
  31. Lee DH, Kim MH, Guo LZ, Park MK, Yi SJ : Lower loading dose of prasugrel compared with conventional loading doses of clopidogrel and prasugrel in Korean patients undergoing elective coronary angiography: a randomized controlled study evaluating pharmacodynamic efficacy. Korean Circ J 44 : 386-393, 2014 https://doi.org/10.4070/kcj.2014.44.6.386
  32. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. : Aspirin resistance: position paper of the working group on aspirin resistance. J Thromb Haemost 3 : 1309-1311, 2005 https://doi.org/10.1111/j.1538-7836.2005.01351.x
  33. Nishi H, Nakahara I, Matsumoto S, Hashimoto T, Ohta T, Sadamasa N, et al. : Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy. J Neurointerv Surg 8 : 949-953, 2016 https://doi.org/10.1136/neurintsurg-2015-011844
  34. Nordeen JD, Patel AV, Darracott RM, Johns GS, Taussky P, Tawk RG, et al. : Clopidogrel resistance by P2Y12 platelet function testing in patients undergoing neuroendovascular procedures: incidence of ischemic and hemorrhagic complications. J Vasc Interv Neurol 6 : 26-34, 2013
  35. Pandya DJ, Fitzsimmons BF, Wolfe TJ, Hussain SI, Lynch JR, Ortega-Gutierrez S, et al. : Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose. J Neuroimaging 20 : 64-69, 2010 https://doi.org/10.1111/j.1552-6569.2008.00322.x
  36. Paniccia R, Priora R, Liotta AA, Abbate R : Platelet function tests: a comparative review. Vasc Health Risk Manag 11 : 133-148, 2015 https://doi.org/10.2147/VHRM.S44469
  37. Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. : Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363 : 1704-1714, 2010 https://doi.org/10.1056/NEJMoa1008410
  38. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C : Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 : 2373-2383, 2005 https://doi.org/10.1056/NEJMra052717
  39. Pierot L, Wakhloo AK : Endovascular treatment of intracranial aneurysms: current status. Stroke 44 : 2046-2054, 2013 https://doi.org/10.1161/STROKEAHA.113.000733
  40. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK : Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 29 : 281-285, 2008 https://doi.org/10.3174/ajnr.A0818
  41. Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, et al. : PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics 22 : 159-165, 2012 https://doi.org/10.1097/FPC.0b013e32834d4962
  42. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. : Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 123 : 474-482, 2011 https://doi.org/10.1161/CIRCULATIONAHA.110.965640
  43. Stetler WR, Chaudhary N, Thompson BG, Gemmete JJ, Maher CO, Pandey AS : Prasugrel is effective and safe for neurointerventional procedures. J Neurointerv Surg 5 : 332-336, 2013 https://doi.org/10.1136/neurintsurg-2012-010302
  44. Tan LA, Keigher KM, Munich SA, Moftakhar R, Lopes DK : Thromboembolic complications with pipeline embolization device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value. J Neurointerv Surg 7 : 217-221, 2015 https://doi.org/10.1136/neurintsurg-2014-011111
  45. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. : Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 : 2261-2273, 2013 https://doi.org/10.1016/j.jacc.2013.07.101
  46. Yu KS, Park KW, Kelly RP, Gu N, Payne C, Small DS, et al. : Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. J Cardiovasc Pharmacol 62 : 72-77, 2013 https://doi.org/10.1097/FJC.0b013e318290d9e1

Cited by

  1. Preliminary Experience of Neuroform Atlas Stenting as a Rescue Treatment after Failure of Mechanical Thrombectomy Caused by Residual Intracranial Atherosclerotic Stenosis vol.64, pp.2, 2019, https://doi.org/10.3340/jkns.2020.0146
  2. Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives vol.42, pp.12, 2021, https://doi.org/10.3174/ajnr.a7303